Rosiglitazone increases small dense low-density lipoprotein concentration and decreases high-density lipoprotein particle size in HIV-infected patients.
Rosiglitazone increases small dense low-density lipoprotein concentration and decreases high-density lipoprotein particle size in HIV-infected patients.
复制标题
罗格列酮可增加 HIV 感染患者的小密低密度脂蛋白浓度并降低高密度脂蛋白颗粒大小。
DOI：
10.1097/qad.0b013e3282f25123
复制
发表时间：
2007
期刊：
影响因子：
--
通讯作者：
Grinspoon,Steven
中科院分区：
文献类型：
--
作者：
Hadigan,Colleen;Mazza,Sasha;Crum,Dana;Grinspoon,Steven
After 12 weeks of rosiglitazone treatment, significant increases in total and small dense low-density lipoprotein, and the total: high-density lipoprotein (HDL)-cholesterol ratio were found. The large HDL concentration and HDL particle size decreased significantly with rosiglitazone compared with placebo. These data indicate the production of a more atherogenic lipid profile with rosiglitazone, a consideration when selecting treatment for the growing population of HIV-infected patients with type 2 diabetes and dyslipidemia.
